175 related articles for article (PubMed ID: 16629780)
1. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study.
Briggs AH; Bousquet J; Wallace MV; Busse WW; Clark TJ; Pedersen SE; Bateman ED;
Allergy; 2006 May; 61(5):531-6. PubMed ID: 16629780
[TBL] [Abstract][Full Text] [Related]
2. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
[TBL] [Abstract][Full Text] [Related]
4. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
[TBL] [Abstract][Full Text] [Related]
5. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
Markham A; Adkins JC
Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
[TBL] [Abstract][Full Text] [Related]
6. Development of an economic model to assess the cost effectiveness of asthma management strategies.
Price MJ; Briggs AH
Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
[TBL] [Abstract][Full Text] [Related]
7. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
Paggiaro P; Patel S; Nicolini G; Pradelli L; Zaniolo O; Papi A
Respir Med; 2013 Oct; 107(10):1531-7. PubMed ID: 23916740
[TBL] [Abstract][Full Text] [Related]
8. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
10. Seretide: a pharmacoeconomic analysis.
Fritscher L; Chapman KR
J Med Econ; 2008; 11(3):555-70. PubMed ID: 19450105
[TBL] [Abstract][Full Text] [Related]
11. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Bateman ED; Boushey HA; Bousquet J; Busse WW; Clark TJ; Pauwels RA; Pedersen SE;
Am J Respir Crit Care Med; 2004 Oct; 170(8):836-44. PubMed ID: 15256389
[TBL] [Abstract][Full Text] [Related]
12. Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
Pharmacoeconomics; 1999; 16 Suppl 2():i-viii, 1-34. PubMed ID: 10724799
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
Lundbäck B; Jenkins C; Price MJ; Thwaites RM
Respir Med; 2000 Jul; 94(7):724-32. PubMed ID: 10926346
[TBL] [Abstract][Full Text] [Related]
14. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Oba Y
Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
Rely K; McQuire SE; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
18. Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
Pavord I; Woodcock A; Parker D; Rice L;
Respir Res; 2007 Sep; 8(1):67. PubMed ID: 17897478
[TBL] [Abstract][Full Text] [Related]
19. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.
Edin HM; Andersen LB; Schoaf L; Scott-Wilson CA; Ho SY; Ortega HG
Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604
[TBL] [Abstract][Full Text] [Related]
20. Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations.
Hagiwara M; Delea TE; Stanford RH
Allergy Asthma Proc; 2014; 35(1):54-62. PubMed ID: 24433597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
